GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stella Pharma Corp (TSE:4888) » Definitions » Sloan Ratio %

Stella Pharma (TSE:4888) Sloan Ratio % : 0.00% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Stella Pharma Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Stella Pharma's Sloan Ratio for the quarter that ended in Sep. 2024 was 0.00%.

As of Sep. 2024, Stella Pharma has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Stella Pharma Sloan Ratio % Historical Data

The historical data trend for Stella Pharma's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Pharma Sloan Ratio % Chart

Stella Pharma Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Sloan Ratio %
Get a 7-Day Free Trial -60.46 6.66 14.07 1.82 3.20

Stella Pharma Quarterly Data
Mar19 Mar20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Stella Pharma's Sloan Ratio %

For the Biotechnology subindustry, Stella Pharma's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stella Pharma's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stella Pharma's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Stella Pharma's Sloan Ratio % falls into.



Stella Pharma Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Stella Pharma's Sloan Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (A: Mar. 2024 )-Cash Flow from Operations (A: Mar. 2024 )
-Cash Flow from Investing (A: Mar. 2024 ))/Total Assets (A: Mar. 2024 )
=(-763.749--876.837
--9.01)/3820.622
=3.20%

Stella Pharma's Sloan Ratio for the quarter that ended in Sep. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2024 )
=(-598.05-0
-0)/5205.185
=-11.49%

Stella Pharma's Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was -140.157 (Sep. 2023 ) + -163.705 (Dec. 2023 ) + -294.188 (Mar. 2024 ) + 0 (Sep. 2024 ) = 円-598.1 Mil.
Stella Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2024 was 0 (Sep. 2023 ) + 0 (Dec. 2023 ) + 0 (Mar. 2024 ) + 0 (Sep. 2024 ) = 円0.0 Mil.
Stella Pharma's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 was 0 (Sep. 2023 ) + 0 (Dec. 2023 ) + 0 (Mar. 2024 ) + 0 (Sep. 2024 ) = 円0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stella Pharma  (TSE:4888) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2024, Stella Pharma has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Stella Pharma Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Stella Pharma's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Stella Pharma Business Description

Traded in Other Exchanges
N/A
Address
3-2-7 Korai-bashi, Chuo-ku, Osaka Prefecture, Osaka, JPN, 541-0043
Stella Pharma Corp is a therapeutic drug research and development company. It is focused on the development of boron compounds, particularly used in boron neutron capture therapy (BNCT). The BNCT is a form of cancer radiation therapy for destroying cancer cells.

Stella Pharma Headlines

No Headlines